Investigational lymphoma drug shows positive results

HuMax-CD20 has shown positive results in phase I/II studies in the treatment of non-Hodgkin’s lymphoma (NHL), Danish biotech firm Genmab said on Monday.

The company said 55% of trial patients achieved a clinical response, with a 27% complete response rate for treatment of relapsed refractory follicular NHL.”The significant responses of NHL patients in this study are very encouraging and we are pleased to see that HuMax-CD20 seems to have a very good safety profile,” Genmab Chief Executive Lisa Drakeman said in a statement.The data will be presented later today at the annual meeting of the American Society of Hematology in San Diego, the company said.(Source: Reuters Health: Oncolink: December 2004.)